UK ROX
The aim of the UK-ROX trial is to evaluate the clinical and cost-effectiveness of conservative oxygen therapy for invasively ventilated adults in intensive care.
​
The research question is: in non-elective adults receiving mechanical ventilation and supplemental oxygen in ICU (population) - is conservative oxygen therapy (intervention) superior to usual oxygen therapy (comparator) in terms of all-cause mortality at 90 days (outcome) ?
​
The trial SOPs contain relevant examples of conditions where clinicians may exclude patients (at their discretion) because conservative oxygen therapy is either indicated or contraindicated.
INCLUSION CRITERIA
Adults admitted to ICU who are receiving invasive mechanical ventilation, enrolled within 12 hours of fulfilling the below eligibility criteria.
1. Age >18
2. Receiving invasive mechanical ventilation in the ICU following an unplanned ICU admission (ie not admitted after an elective procedure) OR invasive mechanical ventilation started in the ICU (ie the patient was intubated in the ICU)
3. Receiving supplemental oxygen (fractional inspired concentration of oxygen (FiO2)>0.21 at the time of enrolement
EXCLUSION CRITERIA
1. Previously randomised into UK-ROX in the last 90 days
2. Currently receiving extracorporeal membrane oxygenation (ECMO)
3. The treating clinician considers that one study treatment arm is either indicated or contraindicated
